Cellcor & Organon Technika/Biotech Research Institute
Executive Summary
Jointly sponsored Phase I clinical trial of the companies' cellular therapy technologies will involve approximately 15 patients with stage IV metastatic renal cell carcinoma who will receive OT/BRI's active specific immunotherapy followed by Cellcor's autolymphocyte therapy. The trial is the first time two cellular therapies have been used together, Cellcor says. The companies believe the synergy of specific and non-specific immune system activation will result in "reduced tumor size and growth rate and prolonged quality survival." The trial will take place at Georgetown's Lombari Cancer Center
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth